SBL Vaccin AB manufactures and distributes vaccines. Its products are used for the treatment of polio, diarrhoea, and cholera diseases. The company distributes products to the healthcare centers, hospitals, schools, and industrial healthcare units. SBL Vaccin was founded in 1957 and is located in Solna, Sweden.

Board of Trustees of Michigan State University, part of Michigan State University, is an American company that trusts Except Educational Religious.

Taiko Pharmaceutical Co., Ltd. engages in the manufacture and sale of general medications particularly non-prescription gastrointestinal drugs and designated quasi drugs. It operates through the following segments: Pharmaceuticals, Infection Control, and Others. The Pharmaceuticals segment handles the sale of gastrointestinal drugs such as Seirogan, Seirogan Toui A, and Seirogan Quick C. The Infection Control segment offers hygiene products such as Cleverin and clev&and. The Others segment provides vinegar-related products. The company was founded by Otojiro Shibata in July 1940 and is headquartered in Osaka, Japan.

Hanmi Science Co., Ltd. engages in the management of its subsidiaries. It is mainly engaged in the manufacturing and selling of pharmaceutical ingredients and intermediates. The company was founded on June 15,1973 and is headquartered in Hwaseong-si, South Korea.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Jilin Qijian Biotechnology Co., Ltd., established on 2004-12-30, The business scope includes chemical intermediates,Intermediates of biological products,Intermediates of traditional Chinese medicine products,research and development,Production,wholesale,retail(except medicines,Except for special approval;Produced with an environmental license);technology development,transfer,Consulting Services and Goods,Technology Import and Export(Except where prohibited by national laws and regulations);Production and sales of APIs(Adenosylmethionine butanedisulfonate,recombinant human growth hormone)and freeze-dried powder,small volume injection,Therapeutic biological products(Recombinant Human Growth Hormone for Injection)(law,Projects prohibited by regulations and decisions of the State Council shall not be operated,Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)**

Active Biotech AB engages in the development of pharmaceutical products. The firm specializes in the medical areas where the immune defense is of significant importance, including neurodegenerative diseases, autoimmune, inflammatory disease, and various forms of cancer. Its portfolio comprises orally active immunomodulatory molecules as well as antibody-based immunotherapy. The company was founded on June 15, 1982 and is headquartered in Lund, Sweden.

LION Bioscience AG is a research company. It offers development and marketing of products that are designed to assist pharmaceutical and biotechnology companies in the identification of drug candidates, and to accelerate the traditional drug discovery process. was founded by Friedrich Halbach in 1990 and is headquartered in San Diego, California.

Vestlandets Innovasjonsselskap AS is a Norwegian private company with domestic subsidiaries, that operates innovation centres.

Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic disorders. The Company's molecules, whose systemic exposure is severely restricted, target transporters and receptors, modulating the uptake of nutrients or inducing secretion of key hormones to produce a therapeutic benefit in patients. The Company's non-systemic products act from within the intestines to avoid potential side effects that could occur with systemic exposure. The Company's lead product, RDX5791, a minimally-absorbed, orally administered NHE3 sodium transport inhibitor, is being developed both for constipation-predominant irritable bowel syndrome (IBS-C) and for prevention of excess dietary sodium absorption, a new treatment modality for high blood pressure. RDX5791 is in phase 2 for IBS-C and a dose-ranging/regimen study for inhibition of excess dietary sodium absorption. Ardelyx is also developing RDX002, a minimally-absorbed, orally administered NaP2b phosphate transport inhibitor for the inhibition of phosphate absorption in patients with chronic kidney disease, and RDX009, a minimally-absorbed, orally administered TGR5 agonist for the treatment of type 2 diabetes through direct induction of intestinal incretins such as GLP-1 and PYY. Both RDX002 and RDX009 are in preclinical development. To date, Ardelyx has raised $56M in venture and angel funding since it was founded in 2007. Ardelyx is located in Fremont, California.

Part of Valneva SE, Valneva Sweden AB is a company headquartered in Solna, Sweden, that manufactures vaccines and medicinal drugs.

Suzhou Jinnuo Biotechnology Co., Ltd., established on 2014-12-05, Business scope includes biological products,medicine,Technology R&D of Cosmetics,technical consulting,technology transfer,Technical Services;Distribution of cosmetics;food sales;Business Management Consulting Services;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)